Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 6:30 PM
Ignite Modification Date:
2025-12-24 @ 6:30 PM
NCT ID:
NCT03019757
Eligibility Criteria:
Inclusion Criteria:
* Subjects must meet the standard clinical criteria of the syndromes of interest
* All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.
* Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.
* Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.
* Subjects must have visual and auditory acuity adequate for testing.
Exclusion Criteria:
* Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment.
* active medical disorder that could preclude participation in this protocol
* Women who are pregnant or are breast feeding
* severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan).
* Subjects in whom English is not the 1st language
* Subjects with educational level less than 12 years
* Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT03019757
Study Brief:
Protocol Section:
NCT03019757